Characteristics of viral vectors for gene therapy
The application of gene therapy in the field of Urology is not limited to cancer therapy but is also being evaluated for non-cancer related bladder dysfunctions as well as erectile dysfunction (ED). This article will review the use of gene therapy for these conditions; the vectors used and limitations associated with different gene delivery systems and the attempts to overcome these shortcomings.
2. Bladder cancer
Bladder cancer is the 7th most common cancer worldwide. It has a natural history of superficial recurrences and local progression. It is estimated that within 18 months of first diagnosis approximately 50% of patients will have a recurrence (Anderson & Naish 2008). Thus there is a need for frequent monitoring of these patients. In the US the estimated life-time cost of therapy for bladder cancer patients with non-muscle invasive disease was US $21.03 million based on a Medicare database (Cooksley et al. 2008). The majority of this is spent on surveillance and the treatment of recurrences. Tumors occur on the luminal surface of the bladder and the architecture of the bladder permits topical intravesical therapies. The bladder is isolated from other organs and tissues and intravesical therapy permits contact with the entire internal surface of the bladder with minimal systemic side-effects.
The present gold standard therapy for superficial bladder cancers is immunotherapy with Mycobacterium bovis, Bacillus Calmette Guerin (BCG) following local transurethral resection of the bladder tumor (TURBT). BCG induces a mononuclear and neutrophilic infiltrate in the bladder wall which results in an inflammatory response as measured by cytokine production that causes sloughing of both tumor and normal cells (Herr and Morales 2008). The presence of IL-2, IL-8 and IL-18 in the urine of patients has been reported to correlate with response to therapy (Thalmann et al. 1997; Thalmann et al. 2000; Saint et al. 2003). Unfortunately, BCG has several shortcomings: it is a live vaccine and commonly causes side effects and occasionally septicemia. In addition some patients (20-42%) do not respond to therapy (Kamat and Lamm 2000). In place of BCG, recombinant cytokines such as IFN-, TNF-, and IL-2 have been used in a number of clinical trials with encouraging results (Glazier et al. 1995; Den Otter et al. 1998; Stavropoulos et al. 2002). However, recombinant cytokines are costly, unstable in urine and have poor permeability across the glycosaminoglycan (GAG) layer of the urothelium. Gene therapy is a natural alternative approach to ensure cytokine production in the bladder environment.
2.1. Viral transfection systems for bladder cancer
Initially replication defective viruses were generated with the sole purpose of gene delivery (Thomas et al. 2003). The viruses evaluated included: Adenovirus (type 2 and 5), Adeno-associated virus (
However, because of the limited transduction capability of some viruses, replicating and conditionally replicating viruses were developed. These viruses amplify the transfection efficiency, as virus transduced cells produce more viruses that can infect the surrounding cells. Replication of wild type viruses also induces cytolysis of infected cells.
2.1.1. Limitations and Improvements
220.127.116.11. Non-specificity of transfection
To reduce non specific viral transduced gene expression, oncolytic adenoviruses have been engineered to express the E1A and E1B genes under the control of the uroplankin II gene promoter (Zhang et al. 2002; He et al. 2009) which limits expression to urothelial cells. Another strategy to target viral replication to tumor cells is to place the adenovirus E1A gene under the control of the telomerase promoter (Lanson et al. 2003), the midkine gene promoter (Terao et al. 2007) or the Cox-2 promoter (Shirakawa et al. 2004). All these genes are highly expressed in tumor cells.
Bladder cancer cells often over-express the epidermal growth factor receptor (EGFR) and targeting EGFR with bi-specific antibodies improved the delivery of adenovirus to cancer cells (van der Poel et al. 2002). A gammaretrovirus carrying a chimeric envelope protein containing a single chain variable fragment (scFv) antibody to the human epidermal growth factor receptor 2 (HER2) was shown to specifically target cells expressing Her2 (Tsai et al. 2010).
18.104.22.168. Transfection efficiency
The internal surface of the bladder is covered by uroplakin proteins and the GAG layer which together provide a barrier to transfection of urothelial cells. Agents that disrupt this protective layer such as ethanol, HCl, dodecyl-B-d-maltoside and sodium dodecyl sulphate have been shown to improve viral transduction of the bladder (Engler et al. 1999; Lin et al. 2002; Ramesh et al. 2004).
Though adenoviruses are the most popular viruses for gene therapy they require adhesion with the cellular coxsackie-adenoviral receptor (CAR) for transduction of mammalian cells. Neoplastic tissue unlike normal bladder cells have reduced CAR expression (Buscarini et al. 2007) as a result of epigenetic control mechanisms (Pong et al. 2003).
|Adenovirus||High with CAR receptor||high||8kb||Transient expression, DNA remains episomal|
|Adeno-associated virus||Good, no receptor||low||4.5kb||Stable, DNA episomes found|
|Herpes simplex virus||High in neurons||high||"/>30kb||Stable in neurons and transient in others, episomal|
|Moloney murine leukemia virus||High in dividing cells||low||8kb||Stable expression, DNA integration into host genome|
|Lentivirus||Non dividing cells||low||8kb||Stable expression, Integration in host chromosome,|
|Canary pox virus||Most cells||low||25kb||Transient expression, Viral DNA limited to cytoplasm|
|Vaccinia virus||Most cells||high||Up to 25kb||Transient expression, Viral DNA limited to cytoplasm|
To circumvent the need for receptor mediated uptake, polymers have been used to enhance adenovirus transfection of bladder cells (Kasman et al. 2009) or even small molecule excipients such as Syn3 (Connor et al. 2001; Yamashita et al. 2002; Nagabhushan et al. 2007). A recent study has shown that CAR receptor expression and thus adenoviral expression can be increased by treatment with histone deacetylase inhibitors (HDACI) such as trichostatin A and sodium phenylbutyrate (Sachs et al. 2004).
22.214.171.124. Previous Immunity
Vaccinia viruses have long been used in man as vaccines against smallpox. This raised the issue of whether previous immunization would block the effectiveness of these viruses as gene delivery vehicles. Intravesical instillation of vaccinia viruses was successfully demonstrated in pre-immunized mice (Lee et al. 1994). The immunogenicity of adenoviruses is a major limitation in most therapeutic strategies. However it may be advantageous in bladder cancer therapy where non-specific inflammation as a consequence of BCG instillation has been associated with tumor removal.
126.96.36.199. Promoter inactivation
Adenovirus genes expressed from a CMV promoter induced better gene expression than those expressed using a RSV promoter (Freund et al. 2000). But quite often the CMV promoter is inactivated
2.2. Non-viral transfection systems for bladder cancer
The strength and weakness of non-viral vectors is the transient expression of the delivered genes. For non-viral gene delivery the genes are encoded on plasmid DNA of bacterial origin. Non-viral delivery agents include liposomes (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, DOTAP), polyethylenimine (PEI), viral envelopes (with fusogenic properties) conjugated to liposomes (Hemagglutinating Virus of Japan (HVJ) liposomes), chitosans as well as physical means such as the use of an electrogun or ultrasound (Harimoto et al. 1998; Lawrencia et al. 2001; Ogawa et al. 2004; Bonnet et al. 2008; Tsai et al. 2009; Zaharoff et al. 2009). Plasmid DNA delivery systems result in cellular entry via the endosomes (Al-Dosari & Gao 2009). Endosomal escape is often difficult and when successful the plasmid DNA is mainly restricted to the cytoplasm. A small amount may make it to the nucleus and exist as episomal DNA molecules that can be lost during replication (Al-Dosari & Gao 2009). Besides the delivery agents, the plasmid DNA sequence can also modulate the efficiency of transfection as discussed below.
2.2.1. Limitations and Improvements
188.8.131.52. Promoter inactivation
It has been reported that the CMV promoter often used for plasmid gene expression does not always result in good gene expression (Loser et al. 1998) as a consequence of promoter inactivation. This can be overcome by using a HDAC inhibitor, as demonstrated with OSU-HDAC42 (Lai et al. 2010). An alternative strategy is to utilize tissue/cancer cell specific promoters such as the COX-2, H19 and human IGF2-P4 gene promoters (Ohana et al. 2002; Zhang et al. 2008; Amit & Hochberg 2010).
184.108.40.206. Transfection efficiency
The primary focus of improving plasmid DNA transfection is improving escape from the endosomes and this is achieved by developing new additives and lipoplexes or even polyplexes that use either acidification or osmotic pressure changes or membrane fusogenic molecules to allow DNA escape (Al-Dosari and Gao 2009). We developed a formulation comprised of DOTAP and Methyl--cyclodextrin solubilized cholesterol (MBC) that transfects urothelial cells
220.127.116.11 Specificity of plasmid expression and activity/duration
Antibodies have been used to target delivery of plasmids to tumor cells. ScFv antibody to Her-2 (Tsai et al. 2009) or transferrin have been demonstrated to successfully target plasmids to tumor cells (Pirollo et al. 2008). The latter strategy targets both primary and metastatic disease when delivered systemically. Targeting of plasmid DNA to the nucleus can also be induced by introducing mammalian transcription factor binding sites in the plasmid and this increased the duration of expression (Gill et al. 2009).
Plasmid DNA expression is transient because of the episomal nature of transfected DNA. In bladder cancer therapy this can be overcome by repeated intravesical instillations. Another strategy to improve gene expression is to add a scaffold matrix attachment region (S/MAR) to the plasmid DNA. S/MAR serve both to ensure prolonged gene expression, by reducing the silencing of plasmid DNA as well as to ensure plasmid DNA replication as episomes (Gill et al. 2009).
Integration of plasmid DNA into chromosomal DNA is achievable now. The techniques used include retroviral integrase (Tanaka et al. 1998), sleeping beauty (SB) transposons (Hackett et al. 2010) or phage recombinase mediated integration (Olivares et al. 2002). Thus in the future a single intravesical instillation may be sufficient for prolonged therapeutic effects.
18.104.22.168. Liposome free delivery
For small molecules such as CpG oligodeoxynucleotides (ODN), intravesical delivery to urothelial cells can be achieved without a transfection agent (Ninalga et al. 2005). But plasmid DNA requires a delivery agent. Nanoparticles (10-100nm in size) with bound plasmid DNA are recognized by cell surface nucleolin on HeLa cells and this results in DNA transport to the nucleus (Chen et al. 2008) and avoidance of endosomal entrapment.
The CpG sequences on plasmid DNA induce inflammation that could reduce gene expression by either destruction of transfected cells or promoter inactivation (Yew et al. 2000). Minicircle DNA (mcDNA), are supercoiled DNA with only the therapeutic gene cassette. They are generated
2.3. Preclinical evaluation of genes and evolving gene therapy strategies
The different categories of genes used successfully in animal studies are listed in Table 2. Both Sub-cutaneous (sc) and orthotopic models of bladder cancer have been used to evaluate gene therapy. While the data from sc studies have shown the efficacy of the expressed genes, it is the orthotopic models that best reflect clinical disease and therapeutic gene delivery. In general regardless of the delivery system or gene delivered tumor growth reduction or even eradication has been reported in murine models of bladder cancer. Most therapeutic schedules used in the animal studies require repeated instillations of the gene delivery vehicle whether it is a viral or non-viral vector. However, a recent study of viral gene delivery of IFN indicated that a high dose could reduce the need for increased intravesical instillations (Tao et al. 2006). Transfection using transposons may also reduce the need for repeated transfection of plasmid DNA.
New therapies aim to combine several strategies at once. These include the use of oncolytic viruses and immune modulation using GMCSF (Cozzi et al. 2001; Ramesh et al. 2006); wild type p53 and ribozyme erb-2 (Irie et al. 2006) and Rb94 or oncolytic viruses and chemotherapeutic drugs (Zhang et al. 2002; Pirollo et al. 2008).
2.4. Gene therapy clinical trials
Table 3 lists several Phase I trials that have been carried out for bladder cancer. However, results from only a few of these trials are published.
Information about completed, on-going and planned trials were obtained from the following sources: gene therapy clinical trials world wide web-site http://www.wiley.com /legacy/wileychi/genmed/clinical/; the clinical trials.gov, US National Institutes of Health and the Genetic Modification Clinical research Information System database http://www.gemcris.od.nih.gov/Contents/GC_HOME.asp and the World Health Organization International Clinical Trials registry platform portal http://www.who.int /ictrp/en/.
A Phase I trial on vaccinia virus instillation showed increased lymphocyte recruitment and the induction of an inflammatory response in the bladder (Gomella et al. 2001). There were no clinical manifestations of vaccinia toxicity indicating the safety and therapeutic potential of this virus as a gene therapy vector. Adenovirus delivery of p53 was also shown to successfully deliver p53 gene to bladder cells but there was no change in immunohistochemical detection of p53 in bladder tissue (Pagliaro et al. 2003). However, adenovirus therapy was safe and well tolerated (Pagliaro et al. 2003). Delivery of adenovirus carrying p53 with a transduction enhancing agent improved p53 gene delivery and protein expression was found in patient tissue samples (Kuball et al. 2002). Though higher doses of the virus were administered, no dose toxicity was observed (Kuball et al. 2002). Similarly no serious adverse effects were reported by Malmstrom et al. from a recently concluded Phase I/IIa trial using AdCD40L (Malmstrom et al. 2010). They observed gene transfer in biopsies and the infiltration of T lymphocytes (Malmstrom et al. 2010).
A plasmid was used to deliver the diphtheria toxin gene under the control of the H19 gene regulatory sequence in a Phase I/IIa trial for non–muscle invasive bladder cancer (Sidi et al. 2008). They reported mild toxicity and observed complete and partial response in some patients. Thus based on these Phase I trials, both non viral and viral vectors appear to be well tolerated in man.
Several new trials are either in progress or about to commence. These use non-viral and viral delivery vectors as listed in Table 3. A proposal for a Phase I trial for intravesical therapy in bladder cancer patients using plasmid DNA carrying the IFN- gene and our liposome based delivery system is being evaluated by the Health Sciences Authority, Singapore.
2.5. Other urological malignancies
Though not covered here several clinical trials are on-going, evaluating gene therapy for prostate and renal cancers. In general the vectors and genes used are similar though tissue specific promoters may differ. Information on these trials can be obtained from the web-sites listed above. Unlike bladder cancer however, gene delivery to these tissues is not as simple. Thus tissue specific targeted gene expression has been developed. Another strategy is the use of macrophages transfected
3. Non-cancer related urological problems
The bladder is made up of a reservoir and an outlet (bladder neck, urethra and urethral sphincter) whose activities are controlled by smooth and striated muscles. There are more patients with bladder dysfunctions related to its primary function of urine storage and voiding than cancer. These include: lower urinary tract symptoms (LUTS), interstitial cystitis (IC), overactive bladder (OAB), spinal cord injuries affecting micturition and urinary incontinence (UI). It is estimated that by 2018, some 2.3 billion people worldwide will be affected by at least one LUTS, OAB, UI and LUTS suggestive of bladder obstruction (Irwin et al. 2011). LUTS is an umbrella term that encompasses urine storage (increased frequency, at least one episode of nocturia per night, urgency and UI), voiding and post-micturition symptoms (Abrams et al. 2003). Another urological problem is erectile dysfunction (ED). Both LUTS and ED are increased with aging and in patients with diabetes (Brown et al. 2005). With the worldwide increase in the incidence of diabetes the incidence of these urological problems will increase.
Most current therapies for the above mentioned conditions are palliative rather than therapeutic. Gene therapy however, may provide a way to cure the disease and the recent review by Christ lists some of these strategies (Christ 2011). Most of the bladder related problems seem to be linked to muscle and neuronal defects and because of the latter the most common vectors used for animals studies of bladder dysfunctions are HSV vectors.
3.1. Urinary incontinence
Urinary incontinence is a general term used to cover three types of incontinence namely stress, urge and overflow (Chancellor et al. 2001). Stress incontinence occurs when the urinary sphincter muscle is unable to prevent urine leakage following jumping or coughing. This is more common in women than men. Treatment approaches include exercise, surgery and collagen injections into the sphincter muscle. Often multiple injections are required which adds to the cost of treatment and some patients are allergic to bovine collagen. Tissue engineering and
Urge incontinence is characterized by increased urinary urgency and frequency caused by involuntary bladder contractions leading to uncontrollable urine leakage. One study has evaluated intravesical non-viral delivery of a cDNA for the K+ channel and showed that this resulted in increased K+ channels in the smooth muscle of the bladder and amelioration of bladder overactivity (Christ et al. 2001).
Overflow incontinence results from nerve damage such that patients cannot urinate. One common cause is diabetes related neuropathy. Diabetes related cystopathy is often irreversible and restoring bladder functions to diabetic patients is difficult (Sasaki et al. 2002). Animal studies have identified nerve growth factor (NGF) as a good candidate for gene therapy for diabetes induced incontinence (Apfel et al. 1994). HSV delivery of NGF increased NGF in the bladder wall and dorsal root ganglion and improved voiding function in streptozotocin (STZ) induced diabetic rats (Goins et al. 2001; Sasaki et al. 2004).
3.2. Interstitial cystitis/painful bladder syndrome
Interstitial cystitis or painful bladder syndrome occurs predominantly in females (Persu et al. 2010). It is believed to result from underlying inflammation in the bladder. It cannot be adequately treated by drugs and prolonged drug therapy can lead to dependency and tolerance to drugs that may require dose escalation to remain effective. Thus it is a candidate for gene therapy. Delivery of the preproenkephalin gene by HSV (Yokoyama et al. 2009) has been shown to be beneficial in reducing pain. A HSV vector carrying the ionotropic glycine receptor (GlyR) whose expression was induced by glycine had an analgesic effect (Goss et al. 2011). This vector when inoculated into the bladder wall of an inflammation model of IC/PBS in rats was activated by systemic glycine delivery.
3.3. Overactive bladder
Overactive bladder (OAB) is defined as “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence” (Haylen et al. 2010) Detrusor over activity is considered a single marker for OAB. It can occur as a result of spinal injury and could result in a lack of control of micturition. This has been demonstrated in animal models of spinal injury. HSV vector delivery of glutamic acid decarboxylase has shown benefit in a rat model of spinal injury (Miyazato et al. 2009; Miyazato et al. 2010).
3.4. Erectile dysfunction
Approximately 150 million men are projected to suffer from ED and the incidence of ED increases with age. Normal erectile function occurs as a result of 3 synergistic events namely: neurological mediated penial arterial inflow increase; cavernosal smooth muscle relaxation and restriction of venous outflow from the penis (Andersson & Wagner 1995). In ED one or more of these events may be impaired. The penis is an excellent candidate for gene therapy because it is easily accessible, has limited blood flow and a slow cellular turnover (Bivalacqua & Hellstrom 2001). Though therapy is available for erectile dysfunction there are a significant number of patients who do not respond to available therapy (Yoshimura et al. 2010). The recent review by Harraz et al. provides an excellent overview of gene therapy strategies used in animal models of ED that have been shown to resolve this problem (Harraz et al. 2010). Rather than reproducing that information only recent publications not included in that review are mentioned here. Over expression of the transient receptor potential (TRP) channels 6 (dominant negative) by transfection with a plasmid caused a decrease in calcium levels in the corporal smooth muscle and improved erectile function in diabetic rats (Jung et al. 2010). Using a STZ induced diabetes model to evaluate erectile dysfunction, it was found that implantation of mesenchymal stem cells transfected with VEGF improved erectile function compared to implantation of mesenchymal stem cells alone (Qiu et al. 2011).
3.5. Clinical trials
Only two clinical trials are listed on the http://www.gemcris.od.nih.gov/Contents /GC_HOME.asp for urological conditions unrelated to cancer. One is the Phase I trial for ED and the other is a trial for overactive bladder syndrome. Both trials used plasmid DNA carrying the calcium activated potassium channel (Melman et al. 2007). The results of the Phase I trial for ED indicate the safety of this delivery system.
4. Major issues and future prospects for gene therapy
One major issue is the safety of gene therapy in terms of its impact on the environment as well as long term safety in patients. Schenk-Braat et al found that only half of all registered clinical trials included viral shedding data (Schenk-Braat et al. 2007) and what data was available was primarily for the time after virus delivery and not at the time of delivery. These questions should also be raised for plasmid based gene therapy. Long term follow-up data on patients who have received gene therapy may further ameliorate the safety concerns of this therapy. This will result in gene therapy being more readily applied to other non-malignant conditions. The development of better plasmids and ways to integrate plasmids into the chromosome may lead to the greater use of plasmid rather than viral vectors for urological gene therapy.
MicroRNAs (MiRNA) are new targets for cancer therapy. These are small non-coding RNA molecules that bind to complementary sequences in the protein coding regions of mRNA and block their translation. Their expression levels vary in cancer and normal tissues (Catto et al. 2011). MiRNA-203 and MiRNA-221 have been shown to modulate the growth and apoptosis of human bladder cancer cell lines (Lu et al. 2010; Bo et al. 2011) and these could be new targets for therapy. Given the function of miRNA it is possible that these molecules could also be targets for non-cancer related bladder dysfunctions. This has not yet been explored and identifying such molecules may improve our knowledge of the development of these conditions.
The application of gene therapy for urological conditions is being evaluated in many preclinical disease models. In general the results obtained are encouraging and soon these therapies may move to Phase I trials.
Abrams P. Cardozo L. Fall M. Griffiths D. Rosier P. Ulmsten U. Van Kerrebroeck P. Victor A. Wein A. 2003The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. 61 37 49
Akasaka S. Suzuki S. Shimizu H. Igarashi T. Akimoto M. Shimada T. 2001Suicide gene therapy for chemically induced rat bladder tumor entailing instillation of adenoviral vectors. 92 568 575
Al-Dosari M. S. Gao X. 2009Nonviral gene delivery: principle, limitations, and recent progress. 11 671 681
Amit D. Hochberg A. 2010Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2- 4regulatory sequences. 8, 134.
Anderson B. Naish W. 2008Bladder cancer and smoking. Part 4: efficacy of health promotion. 17 1340 1344
Andersson K. E. Wagner G. 1995Physiology of penile erection. 75 191 236
Apfel S. C. Arezzo J. C. Brownlee M. Federoff H. Kessler J. A. 1994Nerve growth factor administration protects against experimental diabetic sensory neuropathy. 634 7 12
Benedict W. F. Tao Z. Kim C. S. Zhang X. Zhou J. H. Adam L. Mc Conkey D. J. Papageorgiou A. Munsell M. Philopena J. Engler H. Demers W. Maneval D. C. Dinney C. P. Connor R. J. 2004Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. 10 525 532
Bivalacqua T. J. Hellstrom W. J. 2001Potential application of gene therapy for the treatment of erectile dysfunction. 22 183 190
Bo J. Yang G. Huo K. Jiang H. Zhang L. Liu D. Huang Y. 2011microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. 278 786 792
Bonnet M. E. Erbacher P. Bolcato-Bellemin A. L. 2008Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. 25 2972 2982
Brown J. S. Wessells H. Chancellor M. B. Howards S. S. Stamm W. E. Stapleton A. E. Steers W. D. Van Den Eeden. S. K. Mc Vary K. T. 2005Urologic complications of diabetes. 28 177 185
Buscarini M. Quek M. L. Gilliam-Hegarich S. Kasahara N. Bochner B. 2007Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. 78 160 166
Catto J. W. Alcaraz A. Bjartell A. S. De Vere White. R. Evans C. P. Fussel S. Hamdy F. C. Kallioniemi O. Mengual L. Schlomm T. Visakorpi T. 2011MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. .
Chancellor M. B. Yoshimura N. Pruchnic R. Huard J. 2001Gene therapy strategies for urological dysfunction. 7 301 306
Chen L. Chen D. Block E. O’Donnell M. Kufe D. W. Clinton S. K. 1997Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 40subunit homodimer. 159, 351-359.
Chen X. Kube D. M. Cooper M. J. Davis P. B. 2008Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. 16 333 342
Christ G. J. 2011Potential applications of gene therapy/transfer to the treatment of lower urinary tract diseases/disorders. , 255 265
Christ G. J. Day N. S. Day M. Santizo C. Zhao W. Sclafani T. Zinman J. Hsieh K. Venkateswarlu K. Valcic M. Melman A. 2001Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. 281, R 1699 1709
Connor R. J. Engler H. Machemer T. Philopena J. M. Horn M. T. Sutjipto S. Maneval D. C. Youngster S. Chan T. M. Bausch J. Mc Auliffe J. P. Hindsgaul O. Nagabhushan T. L. 2001Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. 8 41 48
Cooksley C. D. Avritscher E. B. Grossman H. B. Sabichi A. L. Dinney C. P. Pettaway C. Elting L. S. 2008Clinical model of cost of bladder cancer in the elderly. 71 519 525
Cozzi P. J. Malhotra S. Mc Auliffe P. Kooby D. A. Federoff H. J. Huryk B. Johnson P. Scardino P. T. Heston W. D. Fong Y. 2001Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. 15 1306 1308
Darquet A. M. Cameron B. Wils P. Scherman D. Crouzet J. 1997A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. 4 1341 1349
Delo D. M. Eberli D. Williams J. K. Andersson K. E. Atala A. Soker S. 2008Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. 102 878 884
Den Otter. W. Dobrowolski Z. Bugajski A. Papla B. Van Der Meijden A. P. Koten J. W. Boon T. A. Siedlar M. Zembala M. 1998Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. 159 1183 1186
Dumey N. Mongiat-Artus P. Devauchelle P. Lesourd A. Cotard J. P. Le Duc A. Marty M. Cussenot O. Cohen-Haguenauer O. 2005In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells. 47 257 263
Engler H. Anderson S. C. Machemer T. R. Philopena J. M. Connor R. J. Wen S. F. Maneval D. C. 1999Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. 53 1049 1053
Fodor I. Timiryasova T. Denes B. Yoshida J. Ruckle H. Lilly M. 2005Vaccinia virus mediated 53gene therapy for bladder cancer in an orthotopic murine model. 173, 604-609.
Freund C. T. Tong X. W. Block A. Contant C. F. Kieback D. G. Rowley D. R. Lerner S. P. 2000Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. 20 2811 2816
Freund C. T. Tong X. W. Rowley D. Engehausen D. Frolov A. Kieback D. G. Lerner S. P. 2003Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. 21 197 205
Gaetano C. Catalano A. Palumbo R. Illi B. Orlando G. Ventoruzzo G. Serino F. Capogrossi M. C. 2000Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. 7 1624 1630
Gill D. R. Pringle I. A. Hyde S. C. 2009Progress and prospects: the design and production of plasmid vectors. 16 165 171
Glazier D. B. Bahnson R. R. Mc Leod D. G. von Roemeling. R. W. Messing E. M. Ernstoff M. S. 1995Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. 154 66 68
Goins W. F. Yoshimura N. Phelan M. W. Yokoyama T. Fraser M. O. Ozawa H. Bennett N. J. de Groat W. C. Glorioso J. C. Chancellor M. B. 2001Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. 165 1748 1754
Gomella L. G. Mastrangelo M. J. Mc Cue P. A. Maguire H. J. Mulholland S. G. Lattime E. C. 2001Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. 166 1291 1295
Goss J. R. Cascio M. Goins W. F. Huang S. Krisky D. M. Clarke R. J. Johnson J. W. Yokoyama H. Yoshimura N. Gold M. S. Glorioso J. C. 2011HSV Delivery of a Ligand-regulated Endogenous Ion Channel Gene to Sensory Neurons Results in Pain Control Following Channel Activation. 19 500 506
Hackett P. B. Largaespada D. A. Cooper L. J. 2010A transposon and transposase system for human application. 18 674 683
Harimoto K. Sugimura K. Lee C. R. Kuratsukuri K. Kishimoto T. 1998In vivo gene transfer methods in the bladder without viral vectors. 81 870 874
Harraz A. Shindel A. W. Lue T. F. 2010Emerging gene and stem cell therapies for the treatment of erectile dysfunction. 7 143 152
Haylen B. T. de Ridder D. Freeman R. M. Swift S. E. Berghmans B. Lee J. Monga A. Petri E. Rizk D. E. Sand P. K. Schaer G. N. 2010An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. 29 4 20
He X. D. Wang Z. P. Wei H. Y. Zhou Q. Wang D. G. Tian J. Q. Fu S. J. Rodriguez R. 2009Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell. 82 209 213
Herr H. W. Morales A. 2008History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. 179 53 56
Horiguchi Y. Larchian W. A. Kaplinsky R. Fair W. R. Heston W. D. 2000Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. 7 844 851
Horinaga M. Harsch K. M. Fukuyama R. Heston W. Larchian W. 2005Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. 66 461 466
Inoue K. Perrotte P. Wood C. G. Slaton J. W. Sweeney P. Dinney C. P. 2000Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. 6 4422 4431
Irie A. Matsumoto K. Anderegg B. Kuruma H. Kashani-Sabet M. Scanlon K. J. Uchida T. Baba S. 2006Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type 53and anti-erbB2 ribozyme, against human bladder cancer cells. 13, 298-305.
Irwin D. E. Kopp Z. S. Agatep B. Milsom I. Abrams P. 2011Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. .
Jung J. H. Kim B. J. Chae M. R. Kam S. C. Jeon J. H. So I. Chung K. H. Lee S. W. 2010Gene transfer of TRPC6 (dominant negative) restores erectile function in diabetic rats. 7 1126 1138
Kamat A. M. Lamm D. L. 2000Intravesical therapy for bladder cancer. 55 161 168
Kasman L. M. Barua S. Lu P. Rege K. Voelkel-Johnson C. 2009Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. 6 1612 1619
Kikkawa K. Fujii R. Kuramoto T. Mori T. Inagaki T. Kohjimoto Y. Iwahashi M. Yamaue H. Hara I. 2009Dendritic cells with transduced survivin gene induce specific cytotoxic T lymphocytes in human urologic cancer cell lines. 74 222 228
Kuball J. Wen S. F. Leissner J. Atkins D. Meinhardt P. Quijano E. Engler H. Hutchins B. Maneval D. C. Grace M. J. Fritz M. A. Storkel S. Thuroff J. W. Huber C. Schuler M. 2002Successful adenovirus-mediated wild-type 53gene transfer in patients with bladder cancer by intravesical vector instillation. 20, 957-965.
Lai M. D. Chen C. S. Yang C. R. Yuan S. Y. Tsai J. J. Tu C. F. Wang C. C. Yen M. C. Lin C. C. 2010An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. 17 203 211
Lanson N. A. Jr Friedlander P. L. Schwarzenberger P. Kolls J. K. Wang G. 2003Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. 63 7936 7941
Lawrencia C. Mahendran R. Esuvaranathan K. 2001Transfection of urothelial cells using methyl-beta-cyclodextrin solubilized cholesterol and Dotap. 8 760 768
Lee S. S. Eisenlohr L. C. Mc Cue P. A. Mastrangelo M. J. Lattime E. C. 1994Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. 54 3325 3328
Lin L. F. Zhu G. Yoo J. J. Soker S. Sukhatme V. P. Atala A. 2002A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium. 168 813 818
Loser P. Jennings G. S. Strauss M. Sandig V. 1998Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. 72 180 190
Loskog A. S. Fransson M. E. Totterman T. T. 2005AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. 11 8816 8821
Lu Q. Lu C. Zhou G. P. Zhang W. Xiao H. Wang X. R. 2010MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. 28 635 641
Malmstrom P. U. Loskog A. S. Lindqvist C. A. Mangsbo S. M. Fransson M. Wanders A. Gardmark T. Totterman T. H. 2010AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial. 16 3279 3287
Mc Garvey T. W. Meng R. D. Johnson O. El -Deiry W. Malkowicz S. B. 2001Growth inhibitory effect of 21and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. 6, 155-162.
Melman A. Bar-Chama N. Mc Cullough A. Davies K. Christ G. 2007Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. 9 143 146
Mitterberger M. Marksteiner R. Margreiter E. Pinggera G. M. Colleselli D. Frauscher F. Ulmer H. Fussenegger M. Bartsch G. Strasser H. 2007Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. 100 1081 1085
Miyake H. Hara I. Hara S. Arakawa S. Kamidono S. 2000Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated 53gene transfer in human bladder cancer model. 56, 332-336.
Miyazato M. Sugaya K. Goins W. F. Wolfe D. Goss J. R. Chancellor M. B. de Groat W. C. Glorioso J. C. Yoshimura N. 2009Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. 16 660 668
Miyazato M. Sugaya K. Saito S. Chancellor M. B. Goins W. F. Goss J. R. de Groat W. C. Glorioso J. C. Yoshimura N. 2010Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats. 184 1204 1210
Muthana M. Giannoudis A. Scott S. D. Fang H. Y. Coffelt S. B. Morrow F. J. Murdoch C. Burton J. Cross N. Burke B. Mistry R. Hamdy F. Brown N. J. Georgopoulos L. Hoskin P. Essand M. Lewis C. E. Maitland N. J. 2011Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. 71 1805 1815
Nagabhushan T. L. Maneval D. C. Benedict W. F. Wen S. F. Ihnat P. M. Engler H. Connor R. J. 2007Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. 18 389 394
Ninalga C. Loskog A. Klevenfeldt M. Essand M. Totterman T. H. 2005CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer. 28 20 27
Ogawa R. Kagiya G. Feril L. B. Jr Nakaya N. Nozaki T. Fuse H. Kondo T. 2004Ultrasound mediated intravesical transfection enhanced by treatment with lidocaine or heat. 172 1469 1473
Ohana P. Bibi O. Matouk I. Levy C. Birman T. Ariel I. Schneider T. Ayesh S. Giladi H. Laster M. de Groot N. Hochberg A. 2002Use of H19 regulatory sequences for targeted gene therapy in cancer. 98 645 650
Olivares E. C. Hollis R. P. Chalberg T. W. Meuse L. Kay M. A. Calos M. P. 2002Site-specific genomic integration produces therapeutic Factor IX levels in mice. 20 1124 1128
Pagliaro L. C. Keyhani A. Williams D. Woods D. Liu B. Perrotte P. Slaton J. W. Merritt J. A. Grossman H. B. Dinney C. P. 2003Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of 53gene therapy. 21, 2247-2253.
Pan J. G. Zhou X. Zeng G. W. Han R. F. 2011Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. 32 301 310
Persu C. Cauni V. Gutue S. Blaj I. Jinga V. Geavlete P. 2010From interstitial cystitis to chronic pelvic pain. 3 167 174
Pirollo K. F. Rait A. Zhou Q. Zhang X. Q. Zhou J. Kim C. S. Benedict W. F. Chang E. H. 2008Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. 14 2190 2198
Pong R. C. Lai Y. J. Chen H. Okegawa T. Frenkel E. Sagalowsky A. Hsieh J. T. 2003Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. 63 8680 8686
Qiu X. Sun C. Yu W. Lin H. Sun Z. Chen Y. Wang R. Dai Y. 2011Combined Strategy of Mesenchymal Stem Cells Injection with VEGF Gene Therapy for the Treatment of Diabetes Associated Erectile Dysfunction. .
Ramesh N. Ge Y. Ennist D. L. Zhu M. Mina M. Ganesh S. Reddy P. S. Yu D. C. 2006CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. 12 305 313
Ramesh N. Memarzadeh B. Ge Y. Frey D. Van Roey M. Rojas V. Yu D. C. 2004Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. 10 697 705
Sachs M. D. Ramamurthy M. Poel H. Wickham T. J. Lamfers M. Gerritsen W. Chowdhury W. Li Y. Schoenberg M. P. Rodriguez R. 2004Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. 11 477 486
Saint F. Kurth N. Maille P. Vordos D. Hoznek A. Soyeux P. Patard J. J. Abbou C. C. Chopin D. K. 2003Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. 107 434 440
Sasaki K. Chancellor M. B. Goins W. F. Phelan M. W. Glorioso J. C. de Groat W. C. Yoshimura N. 2004Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. 53 2723 2730
Sasaki K. Chancellor M. B. Phelan M. W. Yokoyama T. Fraser M. O. Seki S. Kubo K. Kumon H. Groat W. C. Yoshimura N. 2002Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. 168 1259 1264
Sazawa A. Watanabe T. Tanaka M. Haga K. Fujita H. Harabayashi T. Shinohara N. Koyanagi T. Kuzumaki N. 2002Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice. 168 1182 1187
Schenk-Braat E. A. van Mierlo M. M. Wagemaker G. Bangma C. H. Kaptein L. C. 2007An inventory of shedding data from clinical gene therapy trials. 9 910 921
Seth S. Matsui Y. Fosnaugh K. Liu Y. Vaish N. Adami R. Harvie P. Johns R. Severson G. Brown T. Takagi A. Bell S. Chen Y. Chen F. Zhu T. Fam R. Maciagiewicz I. Kwang E. Mc Cutcheon M. Farber K. Charmley P. Houston Jr M. E. So A. Templin M. V. Polisky B. 2011RNAi-based Therapeutics Targeting Survivin and PLK1 for Treatment of Bladder Cancer. .
Shiau A. L. Lin C. Y. Tzai T. S. Wu C. L. 2001Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma. 8 73 81
Shibata M. A. Horiguchi T. Morimoto J. Otsuki Y. 2003Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer. 5 219 231
Shieh G. S. Shiau A. L. Yo Y. T. Lin P. R. Chang C. C. Tzai T. S. Wu C. L. 2006Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. 66 9957 9966
Shirakawa T. Hamada K. Zhang Z. Okada H. Tagawa M. Kamidono S. Kawabata M. Gotoh A. 2004A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. 10 4342 4348
Shokeir A. A. Harraz A. M. El -Din A. B. 2010Tissue engineering and stem cells: basic principles and applications in urology. 17 964 973
Sidi A. A. Ohana P. Benjamin S. Shalev M. Ransom J. H. Lamm D. Hochberg A. Leibovitch I. 2008Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. 180 2379 2383
Siemens D. R. Crist S. Austin J. C. Tartaglia J. Ratliff T. L. 2003Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model. 170 979 984
Stavropoulos N. E. Hastazeris K. Filiadis I. Mihailidis I. Ioachim E. Liamis Z. Kalomiris P. 2002Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study. 36 218 222
Sutton M. A. Berkman S. A. Chen S. H. Block A. Dang T. D. Kattan M. W. Wheeler T. M. Rowley D. R. Woo S. L. Lerner S. P. 1997Adenovirus-mediated suicide gene therapy for experimental bladder cancer. 49 173 180
Tanaka A. S. Tanaka M. Komuro K. 1998A highly efficient method for the site-specific integration of transfected plasmids into the genome of mammalian cells using purified retroviral integrase. 216 67 76
Tanaka M. Grossman H. B. 2003In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. 10 1636 1642
Tao Z. Connor R. J. Ashoori F. Dinney C. P. Munsell M. Philopena J. A. Benedict W. F. 2006Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. 13 125 130
Terao S. Shirakawa T. Kubo S. Bishunu A. Lee S. J. Goda K. Tsukuda M. Hamada K. Tagawa M. Takenaka A. Fujisawa M. Gotoh A. 2007Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. 70 1009 1013
Thalmann G. N. Dewald B. Baggiolini M. Studer U. E. 1997Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. 158 1340 1344
Thalmann G. N. Sermier A. Rentsch C. Mohrle K. Cecchini M. G. Studer U. E. 2000Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. 164 2129 2133
Thomas C. E. Ehrhardt A. Kay M. A. 2003Progress and problems with the use of viral vectors for gene therapy. 4 346 358
Tsai Y. S. Shiau A. L. Chen Y. F. Tsai H. T. Lee H. L. Tzai T. S. Wu C. L. 2009Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model. 27 5383 5392
Tsai Y. S. Shiau A. L. Chen Y. F. Tsai H. T. Tzai T. S. Wu C. L. 2010Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy. 17 37 48
van der Poel H. G. Molenaar B. van Beusechem V. W. Haisma H. J. Rodriguez R. Curiel D. T. Gerritsen W. R. 2002Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. 168 266 272
Wang H. Satoh M. Abe H. Sunamura M. Moriya T. Ishidoya S. Saito S. Hamada H. Arai Y. 2006Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. 68 674 681
Wood M. Perrotte P. Onishi E. Harper M. E. Dinney C. Pagliaro L. Wilson D. R. 1999Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. 6 367 372
Wu Q. Esuvaranathan K. Mahendran R. 2004Monitoring the response of orthotopic bladder tumors to granulocyte macrophage colony-stimulating factor therapy using the prostate-specific antigen gene as a reporter. 10 6977 6984
Wu Q. Mahendran R. Esuvaranathan K. 2003Nonviral cytokine gene therapy on an orthotopic bladder cancer model. 9 4522 4528
Xu H. J. Zhou Y. Seigne J. Perng G. S. Mixon M. Zhang C. Li J. Benedict W. F. Hu S. X. 1996Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. 56 2245 2249
Yamashita M. Rosser C. J. Zhou J. H. Zhang X. Q. Connor R. J. Engler H. Maneval D. C. Karashima T. Czerniak B. A. Dinney C. P. Benedict W. F. 2002Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. 9 687 691
Yew N. S. Zhao H. Wu I. H. Song A. Tousignant J. D. Przybylska M. Cheng S. H. 2000Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. 1 255 262
Yokoyama H. Sasaki K. Franks M. E. Goins W. F. Goss J. R. de Groat W. C. Glorioso J. C. Chancellor M. B. Yoshimura N. 2009Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. 20 63 71
Yoshimura N. Kato R. Chancellor M. B. Nelson J. B. Glorioso J. C. 2010Gene therapy as future treatment of erectile dysfunction. 10 1305 1314
Zaharoff D. A. Hoffman B. S. Hooper H. B. Benjamin C. J. Jr Khurana K. K. Hance K. W. Rogers C. J. Pinto P. A. Schlom J. Greiner J. W. 2009Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. 69 6192 6199
Zang Z. Mahendran R. Wu Q. Yong T. Esuvaranathan K. 2004Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors. 14 713 717
Zhang J. Ramesh N. Chen Y. Li Y. Dilley J. Working P. Yu D. C. 2002Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. 62 3743 3750
Zhang X. Atala A. Godbey W. T. 2008Expression-targeted gene therapy for the treatment of transitional cell carcinoma. 15 543 552
Zhang X. Godbey W. T. 2010Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma. .
Zhang Z. Shirakawa T. Hinata N. Matsumoto A. Fujisawa M. Okada H. Kamidono S. Matsuo M. Gotoh A. 2003Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation. 5 860 867
Zhu Z. S. Lin C. Zhang X. Fu M. Liang X. Zeng F. Lu G. Wu M. 2003Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus 53116, 1860-1863.